Currently, there are 39.04M common shares owned by the public and among those 33.69M shares have been available to trade.
The company’s stock has a 5-day price change of 5.33% and -19.17% over the past three months. ATHA shares are trading -48.47% year to date (YTD), with the 12-month market performance down to -88.05% lower. It has a 12-month low price of $0.22 and touched a high of $3.67 over the same period. ATHA has an average intraday trading volume of 332.29K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 10.18%, 10.10%, and -51.62% respectively.
Institutional ownership of Athira Pharma Inc (NASDAQ: ATHA) shares accounts for 45.08% of the company’s 39.04M shares outstanding.
It has a market capitalization of $11.80M and a beta (3y monthly) value of 3.04. The earnings-per-share (ttm) stands at -$2.07. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.49% over the week and 5.97% over the month.
Analysts forecast that Athira Pharma Inc (ATHA) will achieve an EPS of 0 for the current quarter, 0 for the next quarter and 0 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0 while analysts give the company a high EPS estimate of 0. Earnings per share for the fiscal year are expected to increase by 75.66%, and 29.35% over the next financial year. EPS should grow at an annualized rate of 62.77% over the next five years, compared to -73.94% over the past 5-year period.
Looking at the support for the ATHA, a number of firms have released research notes about the stock. Mizuho stated their Neutral rating for the stock in a research note on September 19, 2024, with the firm’s price target at $5-$0.50. Rodman & Renshaw on their part issued Buy rating on August 19, 2024.
